Hamel Associates’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.9M | Sell |
92,513
-288
| -0.3% | -$33.7K | 3.28% | 7 |
|
|
2026
Q1 | $11.2M | Sell |
92,801
-336
| -0.4% | -$38.8K | 3.18% | 9 |
|
|
2025
Q4 | $9.8M | Buy |
93,137
+795
| +0.9% | +$74.6K | 2.96% | 11 |
|
|
2025
Q3 | $7.75M | Sell |
92,342
-945
| -1% | -$77.8K | 2.38% | 13 |
|
|
2025
Q2 | $7.39M | Buy |
93,287
+7,316
| +9% | +$582K | 2.5% | 12 |
|
|
2025
Q1 | $7.72M | Sell |
85,971
-2,233
| -3% | -$208K | 2.62% | 12 |
|
|
2024
Q4 | $8.77M | Buy |
88,204
+15
| +0% | +$1.55K | 2.82% | 10 |
|
|
2024
Q3 | $10M | Sell |
88,189
-695
| -0.8% | -$82.6K | 3.06% | 9 |
|
|
2024
Q2 | $11M | Sell |
88,884
-775
| -0.9% | -$99.8K | 3.47% | 6 |
|
|
2024
Q1 | $11.8M | Sell |
89,659
-85
| -0.1% | -$10.5K | 3.79% | 4 |
|
|
2023
Q4 | $9.78M | Buy |
89,744
+2,033
| +2% | +$211K | 3.45% | 8 |
|
|
2023
Q3 | $9.03M | Sell |
87,711
-730
| -0.8% | -$78.7K | 3.3% | 7 |
|
|
2023
Q2 | $10.2M | Sell |
88,441
-1,697
| -2% | -$193K | 3.57% | 5 |
|
|
2023
Q1 | $9.59M | Sell |
90,138
-192
| -0.2% | -$20.7K | 3.32% | 6 |
|
|
2022
Q4 | $10M | Sell |
90,330
-2,020
| -2% | -$206K | 3.49% | 6 |
|
|
2022
Q3 | $7.95M | Sell |
92,350
-235
| -0.3% | -$21K | 3.15% | 8 |
|
|
2022
Q2 | $8.44M | Buy |
92,585
+80
| +0.1% | +$7.09K | 3.33% | 7 |
|
|
2022
Q1 | $7.59M | Sell |
92,505
-392
| -0.4% | -$30.9K | 2.7% | 11 |
|
|
2021
Q4 | $7.12M | Buy |
92,897
+1,645
| +2% | +$131K | 2.55% | 11 |
|
|
2021
Q3 | $6.85M | Sell |
91,252
-387
| -0.4% | -$29.4K | 2.67% | 10 |
|
|
2021
Q2 | $7.13M | Sell |
91,639
-6,102
| -6% | -$454K | 2.72% | 10 |
|
|
2021
Q1 | $7.19M | Buy |
97,741
+7,635
| +8% | +$563K | 2.77% | 11 |
|
|
2020
Q4 | $7.03M | Sell |
90,106
-749
| -0.8% | -$57.3K | 2.88% | 9 |
|
|
2020
Q3 | $7.19M | Buy |
90,855
+325
| +0.4% | +$25.5K | 3.19% | 9 |
|
|
2020
Q2 | $6.68M | Sell |
90,530
-131
| -0.1% | -$9.86K | 3.22% | 10 |
|
|
2020
Q1 | $6.66M | Buy |
90,661
+3,788
| +4% | +$298K | 3.51% | 7 |
|
|
2019
Q4 | $7.54M | Buy |
86,873
+183
| +0.2% | +$15K | 3.1% | 8 |
|
|
2019
Q3 | $6.96M | Buy |
86,690
+315
| +0.4% | +$25.2K | 2.97% | 10 |
|
|
2019
Q2 | $6.91M | Buy |
86,375
+1,441
| +2% | +$110K | 3.03% | 8 |
|
|
2019
Q1 | $6.74M | Sell |
84,934
-1,022
| -1% | -$76.4K | 3.03% | 9 |
|
|
2018
Q4 | $6.27M | Buy |
85,956
+1,441
| +2% | +$102K | 3.12% | 7 |
|
|
2018
Q3 | $5.72M | Sell |
84,515
-341
| -0.4% | -$21.7K | 2.48% | 12 |
|
|
2018
Q2 | $4.92M | Buy |
84,856
+917
| +1% | +$51.7K | 2.26% | 15 |
|
|
2018
Q1 | $4.36K | Sell |
83,939
-86
| -0.1% | -$4.64K | 0.29% | 17 |
|
|
2017
Q4 | $4.51M | Sell |
84,025
-2,909
| -3% | -$161K | 2.13% | 15 |
|
|
2017
Q3 | $5.31M | Sell |
86,934
-759
| -0.9% | -$46K | 2.59% | 12 |
|
|
2017
Q2 | $5.36M | Hold |
87,693
| – | – | 2.7% | 12 |
|
|
2017
Q1 | $5.32M | Buy |
87,693
+1,624
| +2% | +$98.5K | 2.71% | 13 |
|
|
2016
Q4 | $4.83M | Buy |
86,069
+210
| +0.2% | +$12.3K | 2.49% | 15 |
|
|
2016
Q3 | $5.11M | Sell |
85,859
-79
| -0.1% | -$4.62K | 2.7% | 11 |
|
|
2016
Q2 | $4.72M | Buy |
85,938
+356
| +0.4% | +$18.9K | 2.45% | 11 |
|
|
2016
Q1 | $4.32M | Buy |
85,582
+10,899
| +15% | +$534K | 2.29% | 15 |
|
|
2015
Q4 | $3.77M | Buy |
74,683
+4,559
| +7% | +$230K | 2.4% | 13 |
|
|
2015
Q3 | $3.31M | Buy |
70,124
+14,211
| +25% | +$755K | 2.35% | 14 |
|
|
2015
Q2 | $3.04M | Buy |
55,913
+16,545
| +42% | +$928K | 2% | 18 |
|
|
2015
Q1 | $2.16M | Sell |
39,368
-603
| -2% | -$34.1K | 1.43% | 24 |
|
|
2014
Q4 | $2.17M | Hold |
39,971
| – | – | 1.41% | 25 |
|
|
2014
Q3 | $2.26M | Sell |
39,971
-498
| -1% | -$28K | 1.51% | 21 |
|
|
2014
Q2 | $2.23M | Buy |
40,469
+1,693
| +4% | +$92.4K | 1.47% | 24 |
|
|
2014
Q1 | $2.1M | Hold |
38,776
| – | – | 1.45% | 24 |
|
|
2013
Q4 | $1.85M | Buy |
+38,776
| New | +$1.77M | 1.3% | 27 |
|
Other funds holding MRK
ECSS
Hamel Associates's MRK Position: Q2 2026 in Review
Hamel Associates reduced its Merck (MRK) stake by 0.31% in Q2 2026, selling an estimated $33.7K and leaving 92,513 shares worth $11.9M. The position accounts for 3.28% of the portfolio, ranked #7.
Hamel Associates first reported a position in MRK in Q4 2013 and has held it in 51 quarters since. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.
- Hamel Associates held 92,513 shares of Merck worth $11.9M as of Q2 2026.
- Hamel Associates sold 288 Merck shares in Q2 2026, an estimated $33.7K.
- Merck made up 3.28% of Hamel Associates's portfolio in Q2 2026, its #7 holding.
- Hamel Associates first reported a position in Merck in Q4 2013 and has held it in 51 quarters since.
- 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.
Based on Hamel Associates's 13F filing for Q2 2026, filed 27 Jul 2026.